A securities class action has been filed against Nektar Therapeutics (NKTR) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nektar securities between February 26, 2025 through December 15, 2025. This case has been filed in the USDC – NDCA.
According to the complaint, during the class period, defendants failed to disclose that: (i) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; (iii) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Plaintiff alleges that on December 16, 2025, Nektar issued a press release during pre-market hours “announc[ing] topline results from the 36-week induction treatment period of the Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin[.]” The press release disclosed that the trial failed to reach statistical significance, which Nektar attributed to the inclusion of four patients who should not have been eligible to participate. On this news, Nektar’s stock price fell $4.14 per share, or 7.77%, to close at $49.16 per share on December 16, 2025.